These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34002944)

  • 1. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
    Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
    Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
    Karasic TB; O'Hara MH; Loaiza-Bonilla A; Reiss KA; Teitelbaum UR; Borazanci E; De Jesus-Acosta A; Redlinger C; Burrell JA; Laheru DA; Von Hoff DD; Amaravadi RK; Drebin JA; O'Dwyer PJ
    JAMA Oncol; 2019 Jul; 5(7):993-998. PubMed ID: 31120501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
    Xavier CB; Marchetti KR; Castria TB; Jardim DLF; Fernandes GS
    J Gastrointest Cancer; 2021 Mar; 52(1):374-380. PubMed ID: 33225411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.
    AlMasri SS; Zenati MS; Desilva A; Nassour I; Boone BA; Singhi AD; Bartlett DL; Liotta LA; Espina V; Loughran P; Lotze MT; Paniccia A; Zeh HJ; Zureikat AH; Bahary N
    Cancer Med; 2021 Oct; 10(20):7233-7241. PubMed ID: 34559451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
    Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
    Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
    Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
    Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sinn M; Sinn BV; Treue D; Keilholz U; Damm F; Schmuck R; Lohneis P; Klauschen F; Striefler JK; Bahra M; Bläker H; Bischoff S; Pelzer U; Oettle H; Riess H; Budczies J; Denkert C
    Clin Cancer Res; 2020 Jul; 26(14):3732-3739. PubMed ID: 32234756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
    Truty MJ; Kendrick ML; Nagorney DM; Smoot RL; Cleary SP; Graham RP; Goenka AH; Hallemeier CL; Haddock MG; Harmsen WS; Mahipal A; McWilliams RR; Halfdanarson TR; Grothey AF
    Ann Surg; 2021 Feb; 273(2):341-349. PubMed ID: 30946090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
    Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
    Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
    Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
    Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
    Yamamoto KN; Nakamura A; Liu LL; Stein S; Tramontano AC; Kartoun U; Shimizu T; Inoue Y; Asakuma M; Haeno H; Kong CY; Uchiyama K; Gonen M; Hur C; Michor F
    PLoS One; 2019; 14(4):e0215409. PubMed ID: 31026288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
    Boone BA; Bahary N; Zureikat AH; Moser AJ; Normolle DP; Wu WC; Singhi AD; Bao P; Bartlett DL; Liotta LA; Espina V; Loughran P; Lotze MT; Zeh HJ
    Ann Surg Oncol; 2015 Dec; 22(13):4402-10. PubMed ID: 25905586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
    Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
    J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
    Chikhladze S; Lederer AK; Kousoulas L; Reinmuth M; Sick O; Fichtner-Feigl S; Wittel UA
    World J Surg Oncol; 2019 Nov; 17(1):185. PubMed ID: 31706323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
    Zeh HJ; Bahary N; Boone BA; Singhi AD; Miller-Ocuin JL; Normolle DP; Zureikat AH; Hogg ME; Bartlett DL; Lee KK; Tsung A; Marsh JW; Murthy P; Tang D; Seiser N; Amaravadi RK; Espina V; Liotta L; Lotze MT
    Clin Cancer Res; 2020 Jul; 26(13):3126-3134. PubMed ID: 32156749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
    Herman JM; Fan KY; Wild AT; Wood LD; Blackford AL; Donehower RC; Hidalgo M; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):458-9. PubMed ID: 24074918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.